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The aim of the study was to obtain United Kingdom-based societal preferences for distinct stages of metastatic breast cancer (MBC)
and six common toxicities. Health states were developed based on literature review, iterative cycles of interviews and a focus group
with clinical experts. They described the burden of progressive, responding and stable disease on treatment; and also febrile
neutropenia, stomatitis; diarrhoea/vomiting; fatigue; hand-foot syndrome (grade 3/4 toxicities) and hair loss. One hundred members
of the general public rated them using standard gamble to determine health state utility. Data were analysed with a mixed model
analysis. The study sample was a good match to the general public of England and Wales by demographics and current quality of life.
Stable disease on treatment had a utility value of 0.72, with a corresponding gain of þ0.07 following a treatment response and a
decline by 0.27 for disease progression. Toxicities lead to declines in utility between 0.10 (diarrhoea/vomiting) and 0.15 (febrile
neutropenia). This study underlines the value that society place on the avoidance of disease progression and severe side effects in
MBC. This may be the largest preference study in breast cancer designed to survey a representative general public sample.
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Incidence rates of breast cancer have continued an upward trend
in recent years, increasing by 70% since 1971 and by 15% in the 10
years to 2000. In 2002, approximately 11500 women died from
breast cancer in England and Wales (Office for National Statistics,
2003).
Recurrence of breast cancer and the diagnosis of metastatic
breast cancer (MBC) can be particularly devastating for women
and their families. Patients’ health-related quality of life (HRQL)
can be impaired by the experience of symptoms from the
metastatic disease, the burden of the treatment and the individual’s
ability to cope (McCorkle, 1973). Decreased functioning necessi-
tates alterations in day-to-day activities, personal relationships,
care-giving demands and psychosocial concerns (Lam and
Fielding, 2003).
Robust, well-designed and validated disease-specific measures of
HRQL exist to measure the impact of disease and treatment in
breast cancer. However, determining the effectiveness of a
treatment within a cost-utility (cost per quality-adjusted life year
or QALY) framework requires the collection of preference- (or
utility-) based HRQL data. One means of doing this is by using the
EuroQol Group (EQ-5D) (Rabin and de Charro, 2001), a generic
preference-weighted HRQL measure that produces an individual
utility score. Patients complete a simple descriptive system,
characterising them into one of 243 possible health states that
have previously been valued by members of the general public.
Generic HRQL instruments may lack the sensitivity of disease-
specific measures, and the generalisability of data collected within
a clinical trial can be limited by the study entry criteria, and drop-
out from the trial that may occur differentially for patients with
severely compromised health or HRQL. If utility values for specific
subgroups or adverse events are required, these data could be
limited if the number of people experiencing such events is low.
An alternative to this approach is to generate detailed health
state descriptions of health states related to MBC. Utility scores for
these health states can be determined by eliciting preferences from
members of the general public or patients. Preferences for health
states can be estimated by eliciting the maximum level of risk (of
being dead) that the individual is willing to accept in order to
avoid each health state (referred to as standard gamble (SG)
(Torrance, 1986; Bennett and Torrance, 1996).
Some reported studies have captured utility data for MBC (Earle
et al, 2000; Perez et al, 2001; Franic and Pathak, 2003; Franic et al,
2005). However, these studies are generally based on the
preferences of patients and/or doctors and do not reflect societal
preferences. There are fewer reports that focus on different stages
specifically within MBC or specific adverse events related to
chemotherapy regimens.
This study was designed to elicit societal preferences for health
states describing different MBC disease states (stable on treatment,
responding disease and progressive disease). In addition, these
disease states were combined with five different grade 3/4 toxicities
and hair loss.
MATERIALS AND METHODS
Development of health states
The development of the health states was based on information
from different sources. This included a rapid literature review,
exploratory interviews with expert physicians, one focus group Received 14 February 2006; revised 17 July 2006; accepted 25 July 2006
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swith oncology specialist nurses and further content validation
interviews. The health states were produced for a societal valuation
study, which would include both women and men. Therefore, they
were designed to be easily understandable, and gender neutral as
far as was possible. The health states also made no explicit
reference to cancer. The health states were designed to describe a
3-week period. They were designed for use in an economic model
where patients will cycle between health states, with transition
probabilities determined from clinical trials.
Rapid literature review
A rapid literature review was conducted, primarily designed to
identify the qualitative nature of the HRQL burden in MBC.
Existing patient preference studies or qualitative studies in this
area were given special attention. We were less interested in
studies that simply reported data from the use of HRQL
questionnaires. Several studies described HRQL in patients with
MBC (Sprangers et al, 1996; Brady et al, 1997; Geels et al, 2000;
Perez et al, 2001; O’Shaughnessy et al, 2002; Chung and Carlson,
2003; Hopwood et al, 2004; Luoma and Hakamies-Blomqvist, 2004;
Jones et al, 2005).
Seven main areas of HRQL and disease burden in MBC were
identified. These included physical, social, sexual, cognitive and
emotional functioning, and toxicities and symptoms (Luoma and
Hakamies-Blomqvist, 2004). The review also highlighted how
frequently disease-specific measures, such as the FACT-B (Brady
et al, 1997) and European Organisation for Research and
Treatment of Cancer Core Quality of Life questionnaire-BR23
(Sprangers et al, 1996), had been used. The content of these
measures provided useful descriptive information regarding ways
in which women are affected by breast cancer.
The six toxicities included in the health states were febrile
neutropenia, hand-foot syndrome, stomatitis, fatigue, diarrhoea
and vomiting (all grade 3/4), and hair loss. Hair loss was included
because it was rated as being a key concern to women receiving
chemotherapy treatment (Hopwood et al, 2004). The toxicities
were selected because they occurred in over 6% of patients in data
from two recent clinical trials in MBC with different therapies
(capecitabine, docetaxel and paclitaxel) (O’Shaughnessy et al,
2002; Jones et al, 2005).
Exploratory interviews
An interview discussion guide was developed to understand the
nature of stable, responding and progressive MBC in terms of the
symptoms and impact on HRQL. The guide queried experts about
the symptom burden that patients’ experience (especially pain and
fatigue), the nature and burden of the toxicities and areas of
functioning (social, sexual, cognitive, physical and emotional). For
each area, specific concerns were noted. For example in emotional
functioning, feelings of worry, hopelessness, anxiety and depres-
sion were explored. Experts were asked to describe patient burden
in three base disease health states – stable on treatment,
responding disease (50% reduction in patient’s five largest
tumours) and progressive disease (25% growth in patient’s five
largest tumours).
Consultant or specialist registrar grade oncologists (n¼7) were
identified via an online database of UK-based medical specialists
and recruited to take part in the interviews. Telephone interviews
were conducted by trained interviewers, recorded and transcribed
by a professional transcription agency.
Clinicians described how pain, fatigue, hair loss and diarrhoea/
vomiting markedly affected HRQL in these patients. The impact of
MBC on physical functioning was addressed using four domains:
self-care, caring for your environment, shopping/outdoor duties
and ability to work. Clinicians reported that physical functioning
varies across different states of tumour response. Those with
responding disease would be able to manage most tasks (except
perhaps the ability to work). Those with stable disease would be
likely to be able to care for themselves, but perhaps not do duties
outside the home and would probably have given up working.
Patients with progressive disease would manage some self-care,
but otherwise would be unable to function at the other levels
without assistance. A good consensus emerged from the clinicians
regarding the impact of MBC on sexual and social functioning.
The severity and impact of treatment-related toxicities was also
described and clinicians reported that they generally did not vary
across disease state. Patients with responding disease were
considered better able to cope with side effects than patients with
stable disease. The impact of symptoms is likely to be greater for
patients with progressive disease as they are less able to cope.
Health states: first draft
The first draft of the health states were produced based upon the
interviews and literature review. Fifteen health states were
developed to reflect accurately the input from the clinicians. The
health states did not make explicit reference to cancer because it
was felt that this may have a significant biasing effect on how
people value them. In the main study, the interviewers believed
that some participants correctly guessed that the states described
cancer, but nobody indicated that they recognised them as breast
cancer. Interviewers did not confirm whether they described
cancer or not.
Health states validation: focus group
A focus group led by a trained facilitator (BN) further explored the
validity of the health states. The health states were reviewed for
appropriateness and accuracy by four oncology specialist nurses.
Changes were made to the states based upon this feedback, much
of it focused on better describing the severity of different aspects.
The nurses concluded that the health states were slightly limited in
their ability to capture the full range of patients’ experience, but
were reasonably accurate descriptions. Some suggested changes
relating to toxicities and symptoms were incorporated.
Health states validation: interviews
Three clinical oncologists were asked to review the health states for
accuracy during an in-depth telephone de-briefing interview.
Qualitative and quantitative differences in HRQL and symptom
burden between varying stages and chemotherapy-related toxi-
cities were examined. Each health state was queried for the
accuracy of each part of the description.
Transcripts from the interviews were independently analysed by
three researchers. The oncologists generally agreed that the health
descriptions were an accurate reflection of the states. A few minor
suggestions were made, relating to the wording.
A final review of the health states was undertaken by two
psychometric experts with expertise in developing measures of
HRQL and health states. Their comments and suggestions, which
did not contradict those of the clinical reviewers, were incorpo-
rated into the health state descriptions at this stage. An example of
one of the health states is included here (Box 1).
Pilot study
The health states were piloted with five members of the general
public in a conventional SG interview. Following the completion of
the interview, participants were de-briefed to identify any
problems in the content of the health states or comprehensibility
and language issues. No issues emerged from the pilot study and
no revisions were needed.
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Members of the public provided estimates of utility for the MBC-
related health states in line with the recommendations of National
Institute for Health and Clinical Excellence (NICE, 2004) and the
Washington Panel on Cost Effectiveness (Gold et al, 1996).
Participants were recruited from Greater London through adver-
tisements in local newspapers and from an existing UBC database
of willing survey participants. Interviews were conducted by
trained interviewers at the UBC offices. The purpose of the
interview was fully explained to participants at the start. All
participants provided written informed consent and completed a
sociodemographic questionnaire. Participants also completed the
EQ-5D to rate their current health.
Health states describing full health, dead, own current health
and worst health (designed to be worse than any of the other MBC
health states) were used in addition to the health states that were
developed from the interviews. The SG interview included two
tasks. visual analogue scale (VAS) and SG utility methods
(Torrance, 1986; Bennett and Torrance, 1996) were used to elicit
participants’ utilities for the health states. Each health state
description (including ‘dead’) was first rated on a VAS referred to
as the ‘feeling thermometer’. This had a lowest value of zero and a
highest value of 100 (anchored by the ‘full health’ card).
In the SG task for each health state, patients were asked to
choose one of three options: (1) to live in the hypothetical health
state with certainty for the next 10 years; (2) to choose between
various probabilities of having either full health or worst health for
the next 10 years; or (3) to indicate that the two previous options
were equal. Probabilities for option 2 (full health and worst health)
were varied sequentially until the patient was indifferent between
them. Finally, the worst health state was assessed, based on a
gamble between full health and dead. If any health states had been
rated as worse than dead in the VAS task, then participants were
asked to choose between the certain prospect of dead and a gamble
between the health state in question and full health. The utility
value for the worst health state was determined against dead and
this was used to recalibrate the values for the other health states on
the dead (0) to full health (1) scale.
Data collection
The study included 18 health states (15 health states developed,
one own health, one full health and one dead state) (Appendix A).
These were considered too many health states for each participant
to review so participants completed some anchor states (stable and
responding disease with no side effects, and progressive disease)
and half of the remaining states (by reviewing one combination of
disease state and toxicity which made 10 in total). Equal
proportions of men and women were recruited.
Statistical analysis
The study was designed to collect data from 100 people. This was
not determined by a formal power analysis partly because there
was no specific hypothesis to test. The demographic and EQ-5D
data were summarised and compared to the UK population. The
demographic profile of the study participants was compared to the
2001 national census data for England and Wales (Office of
National Statistics, 2001). In addition the EQ-5D data were
summarised to determine how closely the sample matched a
previous national survey of health in terms of health status and
HRQL. Percentages of the sample reporting moderate or extreme
problems on each dimension of the EQ-5D were compared to
results of a UK National Survey (Kind et al, 1998).
The health state valuations from the SG interview were analysed
using a mixed model analysis with random effects on the patient
level to determine the change in utility score associated with
moving between stages of disease and from no toxicity to one of
the toxicities included. The raw data were transformed using
a logistic transformation (transformed utility¼log ((1-utility)/
utility)). Negative utility scores were changed to a positive utility
value of 0.02, which very slightly increased the mean utility value
and reduced the variation. This was done in order to obtain a
normal distribution suitable to be used in a standard regression
model. Age would be expected a priori to affect preferences and so
it was also included in the analysis. Older participants have more
experience of disease but also have fewer years of life left on
average both of which may affect their preferences around risk.
A further analysis was also conducted to explore the effect of
gender on participants’ preferences. It was hypothesised that if
participants recognised the health state descriptions as being related
to breast cancer then it is possible that men would view the states
differently to women. Therefore the same mixed model analysis was
undertaken with gender included as a dummy variable. Different
model specifications were compared and, using the Likelihood Ratio
test, a model that included gender and the interaction between gender
and disease progression was settled on as the most parsimonious.
RESULTS
Participant characteristics
Of 106 respondents, 100 completed the full interview (data
collection continued until 100 datasets were available). Six
participants were not included in the final analysis because in
the interviewer’s opinion they failed to understand the SG task.
The demographic profile of the participants was similar to the UK
population data (Table 1). There was a higher proportion of people
from ethnic minorities (28%) in our sample and quite a high
proportion with university education (38%). Apart from these
differences the study sample was a fair representation of the
general public in England and Wales. The sample also had a
similar distribution of HRQL impairments to the national sample
reported by Kind et al (1998). The participants in the present study
were less likely to report severe problems in all the EQ-5D
dimensions. No participants reported extreme problems with
mobility, self-care or pain/discomfort.
The mean EQ-5D VAS score for own current health was 82.49
(s.d.¼16.19) and the mean EQ-5D single index score was 0.922
(s.d.¼0.172). Mean VAS score for own health from the SG
interview in the study sample was 87.2 (s.d.¼13.86). Mean SG
utility score for current health was 0.90 (s.d.¼0.16).
Box 1 The health state designed to describe a patient with metastatic
breast cancer who is stable on treatment but with grade 3/4 febrile
neutropenia
K You have a life-threatening illness which is stable on treatment. You are
receiving cycles of treatment which require you to go to the outpatient
clinic.
K You have recently had a blood disorder which led to you being
hospitalised for about 5 days with a fever and severe flu-like symptoms.
You received intravenous antibiotics because this blood disorder could
have caused you to die within a few days of onset. You are at risk of it
happening again following your next cycle of treatment.
K Your appetite is reduced. You sometimes experience significant pain
which can be treated with painkillers. You are able to visit family and
friends but often have to cut it short because you get tired.
K You are able to wash and dress yourself and do jobs around the home.
Shopping and daily activities take more effort than usual. You were
unable to do these things when you had the fever and flu-like
symptoms.
K You feel less physically attractive than usual and your sexual drive is
reduced.
K You feel quite anxious and depressed. You worry that your disease may
progress in the future.
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The mixed model analysis revealed that all disease states and
toxicities were independently significant predictors of utility
(Table 2). The base state (stable disease with no side effects) had
a utility value of 0.715. Moving to responding disease from stable
on treatment produced a significant utility gain (þ0.075). Moving
from stable disease to progressive disease led to a significant
decrement in utility ( 0.272). The toxicities were all associated
with a significant decrement in utility compared to no toxicity.
Using the results of the mixed model it is possible to estimate a
utility value for any combination of disease states and toxicities.
This is done by adding the parameter estimates from the mixed
and back-transforming them using
expðsum coefficientsÞ
1 þ expðsum coefficientsÞ
For example, a 40-year old patient who is stable on treatment,
with diarrhoea and vomiting, hair loss and fatigue has a utility
value of:
expð0:008871 þ 0:0239 40   0:4629   0:5142   0:5086Þ
1 þ expð0:008871 þ 0:0239 40   0:4629   0:5142   0:5086Þ
¼ 0:37
Age
There was a significant association between study participants’ age
and utility values from the mixed model (P¼0.0006). Stable
disease with no side effects was given a utility value of 0.72 by a
person of 40; while a person aged 50 rated the same health state as
0.77. The utility values presented in Table 3 have been estimated
based upon the preferences of someone aged 38.2 to match the UK
census data (Table 1).
Gender
In the mixed model the gender by progression interaction was
significant (parameter estimate: 0.3973, P¼0.0202) but the gender
term was not (0.09653, P¼0.743) indicating that male participants
placed a greater disutility on disease progression compared to
women. The disutility associated with disease progression was
equal to  0.220 for women (stable disease¼0.725 and disease
progression¼0.505) but equalled  0.322 for men (stable dis-
ease¼0.705 and disease progression¼0.384). Men and women
rated stable disease similarly, and there were no differences in their
interpretation of the toxicities. Note that the disutility changes
with the presence of side effects, because the logistic transforma-
tion is not linear.
Table 2 Results of the mixed model analysis
Parameter Parameter estimate s.e. d.f. t-value P-value
Intercept 0.008871 0.3196 97 0.03 0.9779
Age 0.0239 0.006946 862 3.44 0.0006
Treatment response 0.4063 0.05521 862 7.36 o0.0001
Disease progression  1.1477 0.1031 862  11.14 o0.0001
Febrile neutropenia  0.6603 0.08501 862  7.77 o0.0001
Diarrhoea and vomiting  0.4629 0.09929 862  4.66 o0.0001
Hand-foot syndrome  0.5184 0.09929 862  5.22 o0.0001
Stomatitis  0.6634 0.09929 862  6.68 o0.0001
Fatigue  0.5142 0.09929 862  5.18 o0.0001
Hair loss  0.5086 0.09929 862  5.12 o0.0001
d.f.¼degrees of freedom; s.e.¼standard error. The analysis included 969 observations.
Table 3 Utility value of base state (stable MBC on treatment with no
toxicity) and utility gains and decrements associated with departures from
this health state
Parameter Utility values
Base state – stable disease with no toxicity 0.715
Treatment response +0.075
Disease progression  0.272
Febrile neutropenia  0.150
Diarrhoea and vomiting  0.103
Hand-foot syndrome  0.116
Stomatitis  0.151
Fatigue  0.115
Hair loss  0.114
MBC¼metastatic breast cancer.
Table 1 Demographic profile of study sample suggest one decimal place
for sample results
Study sample
(N¼100)
UK census
and ONS data
2001–2004
Age mean (s.d.) 40.16 (13.59) 38.2
Gender (N/Tot, %female 50% Female 51% Female
Ethnic group
White 72% 92.1%
Black 8% 2.0%
Asian 11% 4.0%
Other (includes mixed race, Jewish, Irish) 9% 1.9%
Employment status
Full time 48% —
Part time 19% —
Home maker 2% 4.6%
Disabled 5% 4.2%
Retired 6% 9.8%
Student 11% 1.9%
Other 9% 2.3%
Education – leaving age
No formal qualifications 3% —
GCSE/O levels (16 years) 16% —
A levels (18 years) 15% —
Vocational or work based 10% —
University degree 38% —
Other 18% —
GCSE¼General Certificate of Secondary Education; ONS¼UK Office of National
Statistics.
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This study reports health state utility values from the UK general
public for health states related to stable, responding and
progressive MBC, and six toxicities related to chemotherapy
treatment. Health state descriptions were developed from inter-
views and focus groups with experts in breast cancer, reviewed by
clinical and psychometric experts and piloted on members of the
general public.
Data from the study show the significance that the general
public place on the changes in HRQL seen in MBC. Disease
progression has the largest impact on HRQL, being associated with
a mean utility decrement of 0.272. However, the data also
underline how important the avoidance of chemotherapy-related
side effects is. Each of the toxicities led to a decline in utility of at
least 0.103. The study revealed that hair loss is given similar
importance, in terms of utility loss, as grade 3/4 side effects such as
fatigue and hand-foot syndrome. Participants considered febrile
neutropenia and stomatitis to be the worst toxicities.
There were also gender differences in the value or disutility that
participants placed on disease progression. Male participants
indicated that they thought there was a greater decline in utility
associated with disease progression compared to female partici-
pants. The reason for this remains unclear but it may be that
female participants considered family responsibilities and child
care more in rating health states and so were less willing to accept
risks to avoid progression.
The analysis revealed that the age of the study participants had a
positive correlation with utility values. Younger participants
considered the health states to be worse than older participants.
This may be because older participants are more risk averse and
less willing to risk their health in the remaining years of life. It is
also possible that older participants give higher ratings to the
health states because they perceived them as less of a departure
from their current health state.
This study employed an efficient method of obtaining utility
values for different disease states and toxicities. This allowed much
greater flexibility in estimating utility values for different
combinations of toxicities and disease states. This arguably allows
for the development of more clinically meaningful analyses of the
impact of treatments. The approach could also be used to capture
different levels of severity, approaches to therapy and provisions of
palliative care. The use of the mixed-model analysis, combined
with efficient designs means that study participants only have to
assess a minimum number of health states and yet it is possible to
estimate utility scores for a large number of combinations.
The present sample was a reasonably good match to the UK
population. Ethnic minorities were over-represented, perhaps
reflecting the population of London rather than the whole of
England and Wales. The present study sample reported lower
frequencies of moderate and/or severe problems on the mobility,
self-care and pain/discomfort dimensions of the EQ-5D (but not
usual activities or anxiety/depression where the distribution of
extreme problems was similar to the results from Kind et al, 1998).
Our participants were required to attend for interview and so
needed to be reasonably mobile, which may explain why fewer
people reported some extreme problems. The study by Kind and
co-workers used a postal survey to collect data, and so people with
poorer levels of mobility could participate more easily.
The study has some significant limitations that deserve to be
highlighted. The health states were developed from a literature
review and interviews with clinicians with no direct input from
patients to validate them. Validating the health states would require
a review from people who have recently experienced each of the
toxicities. It would also require a content validation with people who
are currently receiving treatment for MBC. The present method used
to develop health states is a simple pragmatic approach. We have
tried to improve the validity of the health states through rounds of
interviews and a focus group, including different types of clinical
staff in order to arrive at a consensus. The use of clinicians also
means that we are able to get a broad view of the impact of MBC
based on experience with a large number of patients. This helps us
to avoid the health states reflecting idiosyncratic variation, which
can be very substantial in metastatic disease.
The data from this study are not easy to compare to other
published studies for a number of reasons. A utility value for
febrile neutropenia in MBC without hospitalisation of 0.66 has
been reported, which is slightly higher than the equivalent value of
0.565 in the present study (Launois et al, 1996). This difference is
partly due to the difference in hospitalisation. In addition, values
for stable MBC with toxicities ranging from 0.50 to 0.80 have been
reported, matching the data from the present study (Launois et al,
1996; Hillner et al, 1992). However, both these studies elicited
nurses rather than societal preferences and so it is not easy to
compare them. In a major review of utility scores in oncology,
Earle et al (2000) did not identify any societal-based valuations of
breast cancer health states. Our searches have also failed to find
any other studies that report societal valuations in breast cancer.
Other studies in breast cancer with patients and nurses may also be
difficult to compare because different preference elicitation
methods such as time trade off or rating scales have been used.
This study reports what is probably the largest representative
sample of residents of England and Wales to have stated their
preferences for health states related to MBC. This study may also be
used as a basis for further studies to obtain utility data with larger
samples across UK and also possibly with patients to determine the
weight they place on different outcomes. The methodology has
allowed us to estimate the utility of a very large number of
combinations of side effects and disease states within MBC.
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Appendix A
Health states
Stable MBC with no side effects (please note that the health states
used in the interviews did not include these titles)
  You have a life-threatening illness which is stable on treatment.
You are receiving cycles of treatment which require you to go to
the outpatient clinic.
  Your appetite is reduced. You sometimes experience significant
pain which can be treated with painkillers. You are able to visit
family and friends but often have to cut it short because you get
tired.
  You are able to wash and dress yourself and do jobs around the
home. Shopping and daily activities take more effort than usual.
  You feel less physically attractive than usual and your sexual
drive is reduced.
  You feel quite anxious and depressed. You worry that your
disease may progress in the future.
Stable MBC with febrile neutropenia
  You have a life-threatening illness which is stable on treatment.
You are receiving cycles of treatment which require you to go to
the outpatient clinic.
  You have recently had a blood disorder which led to you being
hospitalised for about 5 days with a fever and severe flu-like
symptoms. You received intravenous antibiotics because this
blood disorder could have caused you to die within a few days of
onset. You are at risk of it happening again following your next
cycle of treatment.
  Your appetite is reduced. You sometimes experience significant pain
which can be treated with painkillers. You are able to visit family
and friends but often have to cut it short because you get tired.
  You are able to wash and dress yourself and do jobs around the
home. Shopping and daily activities take more effort than usual.
You were unable to do these things when you had the fever and
flu-like symptoms.
  You feel less physically attractive than usual and your sexual
drive is reduced.
  You feel quite anxious and depressed. You worry that your
disease may progress in the future.
Stable MBC with fatigue
  You have a life-threatening illness which is stable on treatment.
You are receiving cycles of treatment which require you to go to
the outpatient clinic.
  You often feel extremely tired and weak all over. Your tiredness
is not relieved by rest. Most of the time you are frustrated by
being too tired to do the things you used to do easily.
  Your appetite is reduced. You sometimes experience significant
pain which can be treated with painkillers. You are able to visit
family and friends but often have to cut it short because you get
tired.
  You are able to wash and dress yourself some of the time. You
cannot do jobs around the home, shopping or other daily
activities because you are too tired.
  You feel less physically attractive than usual and your sexual
drive is reduced.
  You feel quite anxious and depressed. You worry that your
disease may progress in the future.
Stable MBC with stomatitis
  You have a life-threatening illness which is stable on treatment.
You are receiving cycles of treatment which require you to go to
the outpatient clinic.
  You have recently had very painful sores in your mouth which
meant that you could not eat or drink properly. The pain from
your mouth disturbed your sleep. You were taking pain
medication and mouthwash to treat it. This lasted for about 7
days. You are at risk of it happening again following your next
cycle of treatment.
  Your appetite is reduced. You sometimes experience significant pain
which can be treated with painkillers. You are able to visit family
and friends but often have to cut it short because you get tired.
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s  You are able to wash and dress yourself and do jobs around the
home. Shopping and daily activities take more effort than usual.
You were unable to do these things when you had the painful
sores in your mouth.
  You feel less physically attractive than usual and your sexual
drive is reduced.
  You feel quite anxious and depressed. You worry that your
disease may progress in the future.
Stable MBC with hand-foot syndrome
  You have a life-threatening illness which is stable on treatment.
You are receiving cycles of treatment which require you to go to
the outpatient clinic.
  You have recently suffered from very painful sores on your
hands and feet. Your feet were so badly blistered that you could
not walk and you had great difficulty using your hands. This
lasted for 3–4 weeks.
  Your appetite is reduced. You sometimes experience significant
pain which can be treated with painkillers. You are able to visit
family and friends but often have to cut it short because you get
tired.
  You are able to wash and dress yourself and do jobs around the
home. Shopping and daily activities take more effort than usual.
You were unable to do these things when you had the sore
hands and feet.
  You feel less physically attractive than usual and your sexual
drive is reduced.
  You feel quite anxious and depressed. You worry that your
disease may progress in the future.
Stable MBC with diarrhoea and vomiting
  You have a life-threatening illness which is stable on treatment.
You are receiving cycles of treatment which require you to go to
the outpatient clinic.
  You recently had a bout of sickness that lasted 2–3 days.
You felt very sick and were vomiting occasionally. You
also had frequent severe diarrhoea. You were taking
medication to treat the diarrhoea and vomiting. You are
at risk of it happening again following your next cycle of
treatment.
  Your appetite is reduced. You sometimes experience significant
pain which can be treated with painkillers. You are able to visit
family and friends but often have to cut it short because you get
tired.
  You are able to wash and dress yourself and do jobs around the
home. Shopping and daily activities take more effort than usual.
You were unable to do these things when you had the sickness
and diarrhoea.
  You feel less physically attractive than usual and your sexual
drive is reduced.
  You feel quite anxious and depressed. You worry that your
disease may progress in the future.
Stable MBC with hair loss
  You have a life-threatening illness which is stable on treatment.
You are receiving cycles of treatment which require you to go to
the outpatient clinic.
  You have lost all of your hair.
  Your appetite is reduced. You sometimes experience significant
pain which can be treated with painkillers. You are able to visit
family and friends but often have to cut it short because you get
tired.
  You are able to wash and dress yourself and do jobs around the
home. Shopping and daily activities take more effort than usual.
  You feel less physically attractive than usual and your sexual
drive is reduced.
  You feel quite anxious and depressed. You worry that your
disease may progress in the future.
Responding MBC with no side effects
  You have a life-threatening illness which is responding to
treatment. You are receiving cycles of treatment which require
you to go to the outpatient clinic.
  Your appetite is returning. You sometimes experience pain
which can be treated with painkillers. You are sometimes tired
but are able to visit family and friends.
  You are able to wash and dress yourself and do jobs around the
home. Shopping and daily activities can sometimes be tiring.
  You sometimes feel less physically attractive and your sexual
drive is reduced.
  You worry about your condition but are somewhat hopeful
about the future.
Responding MBC with febrile neutropenia
  You have a life-threatening illness which is responding to
treatment. You are receiving cycles of treatment which require
you to go to the outpatient clinic.
  You have recently had a blood disorder which led to you being
hospitalised for about 5 days with a fever and severe flu like
symptoms. You received intravenous antibiotics because this
blood disorder could have caused you to die within a few days of
onset. You are at risk of it happening again following your next
cycle of treatment.
  Your appetite is returning. You sometimes experience pain
which can be treated with painkillers. You are sometimes tired
but are able to visit family and friends.
  You are able to wash and dress yourself and do jobs around the
home. Shopping and daily activities can sometimes be tiring.
You were unable to do these things when you had the fever and
flu like symptoms.
  You sometimes feel less physically attractive and your sexual
drive is reduced.
  You worry about your condition but are somewhat hopeful
about the future.
Responding MBC with fatigue
  You have a life-threatening illness which is responding to
treatment. You are receiving cycles of treatment which require
you to go to the outpatient clinic.
  You often feel tired and weak all over. Most of the time you are
frustrated by being too tired to do the things you used to do
easily.
  Your appetite is returning. You sometimes experience pain
which can be treated with painkillers. You sometimes do not
have the energy to see family and friends.
  You are able to wash and dress yourself and do jobs around the
home. Shopping and daily activities take some effort.
  You sometimes feel less physically attractive and your sexual
drive is reduced.
  You worry about your condition but are somewhat hopeful
about the future.
Responding MBC with stomatitis
  You have a life-threatening illness which is responding to
treatment. You are receiving cycles of treatment which require
you to go to the outpatient clinic.
  You have recently had very painful sores in your mouth which
meant that you could not eat or drink properly. The pain from
your mouth disturbed your sleep. You were given pain
medication and mouthwash to treat it. This lasted for about 7
days. You are at risk of it happening again following your next
cycle of treatment.
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s  Your appetite is returning. You sometimes experience pain
which can be treated with painkillers. You sometimes do not
have the energy to see family and friends.
  You are able to wash and dress yourself and do jobs around the
home. Shopping and daily activities can sometimes be tiring.
You were unable to do these things when you had the painful
sores in your mouth.
  You sometimes feel less physically attractive and your sexual
drive is reduced.
  You worry about your condition but are somewhat hopeful
about the future.
Responding MBC with hand-foot syndrome
  You have a life-threatening illness which is responding to
treatment. You are receiving cycles of treatment which require
you to go to the outpatient clinic.
  You have recently suffered from very painful sores on your
hands and feet. Your feet were so badly blistered that you could
not walk and you had great difficulty using your hands. This
lasted for 3–4 weeks.
  Your appetite is returning. You sometimes experience pain
which can be treated with painkillers. You sometimes do not
have the energy to see family and friends.
  You are able to wash and dress yourself and do jobs around the
home. Shopping and daily activities can sometimes be tiring.
You were unable to do these things when you had the sore
hands and feet.
  You sometimes feel less physically attractive and your sexual
drive is reduced.
  You worry about your condition but are somewhat hopeful
about the future.
Responding MBC with diarrhoea and vomiting
  You have a life-threatening illness which is responding to
treatment. You are receiving cycles of treatment which require
you to go to the outpatient clinic.
  You recently had a bout of sickness that lasted 2–3 days. You
felt very sick and were vomiting occasionally. You also had
frequent severe diarrhoea. You were taking medication to treat
the diarrhoea and vomiting. You are at risk of it happening
again following your next cycle of treatment.
  Your appetite is returning. You sometimes experience pain
which can be treated with painkillers. You sometimes do not
have the energy to see family and friends.
  You are able to wash and dress yourself and do jobs around the
home. Shopping and daily activities can sometimes be tiring.
You were unable to do these things when you had the sickness
and diarrhoea.
  You sometimes feel less physically attractive and your sexual
drive is reduced.
  You worry about your condition but are somewhat hopeful
about the future.
Responding MBC with hair loss
  You have a life-threatening illness which is responding to
treatment. You are receiving cycles of treatment which require
you to go to the outpatient clinic.
  You have lost all of your hair.
  Your appetite is returning. You sometimes experience pain
which can be treated with painkillers. You sometimes do not
have the energy to see family and friends.
  You are able to wash and dress yourself and do jobs around the
home. Shopping and daily activities can sometimes be tiring.
  You sometimes feel less physically attractive and your sexual
drive is reduced.
  You worry about your condition but are somewhat hopeful
about the future.
Progressive MBC
  You have a life-threatening illness and your condition is getting
worse. You are on stronger medication to relieve any increasing
pain. You experience severe fatigue. You have lost your appetite
and have experienced significant weight loss.
  You feel too tired to go out or to see family and friends. Some of
your relationships with them are strained.
  You are able to wash and dress yourself with some assistance.
You are often unable to do jobs around the house or other daily
activities. You are reliant on others.
  You feel your physical appearance is deteriorating and you have
little or no sexual drive.
  You feel depressed and feel dependent on your family and
friends. You have little hope for the future.
Worst health
  Your condition is critical. You are receiving strong medication
to relieve any increasing pain and nausea but it is not helping.
You experience constant severe fatigue. You hardly eat and you
have lost a large amount of weight.
  You are too tired to see family and friends and conversing with
visitors has become difficult.
  You may have been moved to a palliative care unit or be
receiving hospice service at home. You are confined to a bed or
chair, and need assistance using the toilet, washing, dressing
and eating, etc.
  Your gaunt, frail physical appearance is alarming to yourself
and your family.
  You feel a burden on loved ones and your lack of independence
is demoralising. You have lost hope for recovery. You are afraid
of dying in pain and have begun discussing your concerns with
your caregivers.
Health state utilities for metastatic breast cancer
A Lloyd et al
690
British Journal of Cancer (2006) 95(6), 683–690 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s